Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222729 · ClinicalTrials.gov registry record · Phase 2
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00222729 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 42 participants.
The verdict
NCT00222729, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of two new drugs pemetrexed (Alimta) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and neck cancer. Currently pemetrexed is approved by the Food and Drug Administration (FDA) for another type of cancer, mesothelioma, but it is not approved for head and neck cancer.
Interventions
- DRUG Bevacizumab
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222729
The ClinicalTrials.gov registry entry for NCT00222729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00222729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222729 about?
NCT00222729 is a clinical study titled "Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer". The purpose of this study is to determine if the combination of two new drugs pemetrexed (Alimta) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and neck cancer. Currently pemetrexed is approved by the Food and Drug Administration (FDA) for another type of cancer, mes...
What is the current status of trial NCT00222729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2005-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00222729?
The interventions under investigation include: Bevacizumab (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00222729?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.